Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
A survey of US hepatologists signals pent-up demand exists for the paradigm-changing HCV treatment, but that not all patients will get the drug right away.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Although doctors still like sales reps, Capgemini and Quantia's researchers find their appeal is on the decline, while digital is on the rise. While age is a factor, it's the workplace that's shaping physician preferences.
The company's new president and possible CEO is expected to have significant latitude to change things.
The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.